Valuation: Insulet Corporation

Market Cap 11.03B 9.65B 8.9B 8.18B 15.5B 1,062B 15.76B 106B 41.68B 519B 41.43B 40.52B 1,788B P/E 2026 *
25.8x
P/E 2027 * 20x
Enterprise Value 11.11B 9.71B 8.96B 8.24B 15.6B 1,069B 15.87B 107B 41.96B 522B 41.71B 40.8B 1,801B EV / Sales 2026 *
3.35x
EV / Sales 2027 * 2.74x
Free-Float
97.63%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Insulet Corporation

1 day+4.60%
1 week+5.35%
Current month+9.53%
1 month+12.91%
3 months-17.23%
6 months-42.04%
Current year-41.33%
1 week 153.84
Extreme 153.84
169.85
1 month 138.79
Extreme 138.79
169.85
Current year 138.79
Extreme 138.79
299.8
1 year 138.79
Extreme 138.79
354.88
3 years 125.82
Extreme 125.82
354.88
5 years 125.82
Extreme 125.82
354.88
10 years 30.69
Extreme 30.69
354.88
Manager TitleAgeSince
Chief Executive Officer 55 2025-04-27
Director of Finance/CFO 53 2025-09-29
Compliance Officer 50 2022-11-30
Director TitleAgeSince
Chairman 61 2018-12-31
Director/Board Member 61 2015-07-26
Director/Board Member 59 2017-08-09
Date Insider Type Main position Quantity % Market Cap.
06-30Free

Director

1,355 0.0019%
06-30Other

Director

0 0%
06-29Free

Director

144 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
+4.60%+5.35%-42.15%-42.09% 11.03B
+10.74%+4.94%-24.80%-7.42% 155B
+4.06%+2.03%-6.37%-3.06% 103B
+2.44%+0.13%+1.68%+57.62% 57.7B
-1.11%+4.77%+38.09%+52.37% 52.27B
+2.39%+5.38%-10.83%-38.06% 42.68B
+2.73%-0.58% - - 33.35B
+7.14%+6.83%-7.27%-43.24% 28.06B
+0.98%+1.47%+61.74%-5.40% 25.36B
-0.85%+4.34%-3.58%-18.20% 21.03B
Average +3.29%+0.05%+0.72%-5.28% 53B
Weighted average by Cap. +4.92%-1.71%-4.16%+1.55%

Financials

2026 *2027 *
Net sales 3.32B 2.9B 2.68B 2.46B 4.66B 319B 4.74B 31.96B 12.54B 156B 12.47B 12.19B 538B 3.93B 3.43B 3.17B 2.91B 5.52B 378B 5.61B 37.81B 14.84B 185B 14.75B 14.42B 637B
Net income 432M 378M 348M 320M 607M 41.57B 617M 4.16B 1.63B 20.32B 1.62B 1.59B 70.04B 564M 493M 455M 418M 793M 54.28B 806M 5.43B 2.13B 26.53B 2.12B 2.07B 91.45B
Net Debt 75.17M 65.72M 60.62M 55.73M 106M 7.23B 107M 724M 284M 3.54B 282M 276M 12.18B -283M -247M -228M -210M -397M -27.22B -404M -2.72B -1.07B -13.31B -1.06B -1.04B -45.86B
Logo Insulet Corporation
Insulet Corporation specializes in the design, manufacture and marketing of medical devices intended to improve the lives of people with insulin-dependent diabetes. In addition, the group offers non-insulin subcutaneous drug delivery systems used in several therapeutic areas. Net sales break down by family of products as follows: - Insulin pump therapy systems (98.7%): continuous insulin management and delivery systems (Omnipod® and Omnipod DASH® brands) and automated insulin administration systems (Omnipod® 5 brand); - non-insulin drug administration systems (1.3%): in particular pre-filled syringes for the Neulasta® Onpro® kit (intended for the treatment of neutropenia in patients treated with chemotherapy). At the end of 2025, the group had 2 production sites located in the United States and in China. The United States account for 72.2% of net sales.
Employees
5,400
Date Price Change Volume
26-07-16 US$166.67 +4.64% 411,658
26-07-15 US$159.28 +0.10% 1,332,050
26-07-14 US$159.12 -1.81% 1,942,227
26-07-13 US$162.06 +0.48% 1,616,899
26-07-10 US$161.28 +1.89% 723,320
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
159.28USD
Average target price
238.22USD
Spread / Average Target
+49.56%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PODD Stock